Personalized prostate cancer attack: does your Tumor's DNA hold the key?

NCT ID NCT04812366

Recruiting now Disease control Sponsor: University of British Columbia Source: ClinicalTrials.gov ↗

First seen Jul 31, 2026 · Last updated Aug 14, 2026 · Updated 1 time

Summary

This trial tests whether tailoring prostate cancer therapy to the genetic makeup of a person's tumor can improve the response before surgery. Men with high-risk localized prostate cancer receive initial hormone therapy while their tumor is genetically analyzed, then are assigned to a treatment arm—either hormone therapy alone or combined with chemotherapy, a targeted drug, or immunotherapy. The goal is to see if this personalized approach leads to better tumor shrinkage and outcomes after prostate removal.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: A combination of hormone therapy (apalutamide, abiraterone, prednisone), chemotherapy (docetaxel), targeted therapy (niraparib), and immunotherapy (atezolizumab), selected based on tumor genetics.
What this could lead to: If successful, this approach could lead to more personalized, effective prostate cancer treatment, potentially reducing recurrence after surgery.
What could go wrong: This is an early-phase trial, so results may not confirm benefit. Side effects from combination therapies could be significant, and not all participants may respond.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTATE CANCER

Contacts and locations

Locations

Dana-Farber Cancer Institute / Beth Israel Deaconess Medical Center
RECRUITING

Boston, Massachusetts, 02115, United States
Fred Hutchinson Cancer Center
RECRUITING

Seattle, Washington, 98109, United States
London Health Sciences Centre
RECRUITING

London, Ontario, N6A 5W9, Canada
Ottawa Hospital Research Institute (OHRI)
RECRUITING

Ottawa, Ontario, K1H 8L6, Canada
U.T. MD Anderson Cancer Center
RECRUITING

Houston, Texas, 77030, United States
University Health Network
RECRUITING

Toronto, Ontario, M5G 2C4, Canada
University of California Davis
RECRUITING

Sacramento, California, 95817, United States
University of Michigan Health
RECRUITING

Ann Arbor, Michigan, 48109-5946, United States
Vancouver Prostate Centre
RECRUITING

Vancouver, British Columbia, V5Z 1M9, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.